RP23-480B19.10 Inhibitors
Chemical inhibitors of RP23-480B19.10 act by targeting the acetylation status of this histone protein, a post-translational modification essential for the regulation of chromatin structure and function. Trichostatin A, Vorinostat, Sodium Butyrate, Panobinostat, Valproic Acid, Entinostat, Romidepsin, Belinostat, Mocetinostat, Givinostat, Chidamide, and Tacedinaline are all inhibitors that prevent the deacetylation of RP23-480B19.10, which is typically mediated by histone deacetylases (HDACs). By inhibiting HDACs, these chemicals maintain RP23-480B19.10 in an acetylated state. This acetylation reduces the protein's ability to compact DNA within the chromatin, which is a fundamental role of histone proteins. Consequently, the persistent acetylation leads to a more open chromatin structure, affecting the normal function of RP23-480B19.10 in chromatin condensation and remodeling.
Trichostatin A and Vorinostat, for instance, are broad HDAC inhibitors that directly affect RP23-480B19.10's ability to facilitate chromatin compaction by ensuring that the histone remains acetylated. Sodium Butyrate and Valproic Acid, although they are weaker HDAC inhibitors, still significantly contribute to the acetylation maintenance of histones, including RP23-480B19.10. More selective inhibitors like Entinostat target specific classes of HDACs that likely interact directly with RP23-480B19.10, while Panobinostat is known for its potent inhibitory effect on a wider range of HDACs, leading to more pronounced acetylation and subsequent inhibition of chromatin condensing activity. The varied inhibition profiles of Belinostat, Mocetinostat, and Romidepsin also contribute to the sustained hyperacetylated state of RP23-480B19.10, each with their nuanced interactions with the HDACs that regulate the histone's acetylation levels. Lastly, emerging inhibitors such as Givinostat, Chidamide, and Tacedinaline further expand the array of chemical tools that can modulate the acetylation status of RP23-480B19.10, ensuring that this histone protein remains in a state that is not conducive to DNA compaction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). Since RP23-480B19.10 is a histone protein, HDAC inhibition maintains acetylation of histones, thus inhibiting the function of histone deacetylases on RP23-480B19.10, leading to a more open chromatin structure and reduced ability of RP23-480B19.10 to compact DNA. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, also known as SAHA, is another HDAC inhibitor which would prevent the deacetylation of histone proteins including RP23-480B19.10. This inhibition results in the persistence of acetylated histones, thereby decreasing the ability of RP23-480B19.10 to condense chromatin effectively. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate acts as an HDAC inhibitor, which leads to hyperacetylation of histones such as RP23-480B19.10. By inhibiting HDACs, it prevents deacetylation, thus reducing the ability of RP23-480B19.10 to compact chromatin. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent HDAC inhibitor that would disrupt the function of RP23-480B19.10 by maintaining its acetylation status, leading to a decrease in its chromatin condensing activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid is known to inhibit HDACs, which would keep histones including RP23-480B19.10 in an acetylated state, thus inhibiting its chromatin remodeling ability. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits class I HDACs, which would result in the hyperacetylation of histone proteins such as RP23-480B19.10, thereby inhibiting their function in chromatin condensation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
As an HDAC inhibitor, Romidepsin would prevent the deacetylation of RP23-480B19.10, leading to its functional inhibition by keeping the chromatin structure open. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is an HDAC inhibitor that would inhibit the deacetylation activity on histones including RP23-480B19.10, thereby maintaining a relaxed chromatin structure and inhibiting the normal function of histones. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat inhibits class I and IV HDACs, which would result in the inhibition of deacetylation of histones such as RP23-480B19.10, affecting its role in chromatin compaction. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Givinostat is an HDAC inhibitor that by inhibiting the deacetylation of histone proteins like RP23-480B19.10, would lead to an inhibition of the histone's function in chromatin remodeling. | ||||||